Navigation Links
Pharmos Corporation Reports 2011 Second Quarter Results
Date:8/8/2011

s related to conducting a non-human primate toxicology study needed for this trial. These increases were slightly offset by a reduction of various facility related expenses as the Company continued to reduce overall facility costs.

General and administrative expenses for the second quarter of 2011 decreased by $41,077, or 14%, from $300,492 in 2010 to $259,415 in 2011. The primary reductions were a $30,000 reduction in consultant and professional fees and an $11,000 reduction in salaries and benefits. Professional fees have decreased as there were business development fees in 2010 related to a possible reverse merger candidate which eventually was not pursued. The decrease in payroll costs in 2011 reflects lower stock compensation costs and the elimination of an administrative position in 2010.  

At June 30, 2011, the Company had approximately $2.1 million in cash and cash equivalents which is expected to be sufficient to fund current operations through at least March 31, 2012.  

Six-months Ended June 30, 2011For the six months ended June 30, 2011, Pharmos recorded a net loss of $1.1 million, or $0.02 per share compared to a net loss of $0.9 million, or $0.02 per share for the six months ended June 30, 2010.  

Research & development expenses for the first half of 2011 increased by $269,896 or 119% from $226,358 in 2010 to $496,254 in 2011. The primary areas include a $142,000 increase in clinical study fees and a $167,000 increase in consultant and professional fees which were offset by a $39,000 reduction in various other areas. Consulting and professional fees increased substantially as the Company conducted work in preparation for initiating a proof-of-concept trial in gout patients using Levotofisopam. Clinical study fees increased due to costs related to manufacturing capsules needed for this trial and costs related to conducting a non-human primate toxicology study. These increases were slightly offset by a red
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
2. Pharmos Issues Business Update on Dextofisopam Trial and Financing
3. Pharmos Corporation Reports 2009 Third Quarter Results
4. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
5. Pharmos Corporation Reports 2010 Third Quarter Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. CEL-SCI Corporation Releases Letter to Shareholders
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
10. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 Perrigo ... commented on the Mylan N.V. ("Mylan") (NASDAQ: MYL ... acquire Perrigo. "Our views of Mylan,s offer ... to be, based on our Board,s careful reflection of ... depend on the limited choices that Mylan has allowed ...
(Date:8/28/2015)... Aug. 28, 2015 , Joint ... Ra from Biostar , Published in ,Stem Cells ... of lifespan through multiple IV administration of Adipose-derived MSC ... life expectancy found , Commercialization within 5 years ... the possibility that adult mesenchymal stem cells (MSCs) may ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
... Calif., Feb. 28, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... positive preliminary clinical data from its Phase 1 trial ... HIV-infected subjects who are currently on highly active antiretroviral ... suboptimal CD4+ T-cell counts.  The study is designed to ...
... /PRNewswire/ -- Intuity Medical, Inc .™, ... announced that it has secured a $20M credit facility ... and Oxford Finance Corporation . The funds ... commercialize POGO™, a fully-integrated blood glucose monitoring system. ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 2Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 3Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 4Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 5Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections 6Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 2Intuity Medical Secures $20M Credit Facility From Silicon Valley Bank and Oxford Finance Corporation 3
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Medical Solutions, ... 2015 Best Places to Work in Healthcare by Modern Healthcare and will ... , Now in its eighth year, the Best Places to Work in Healthcare ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ground ... the Food and Drug Administration to eliminate submental fat, also known as the double ... among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , Developed ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... is dedicated to distributing health information technology innovation to transform quality and efficiency ... of the survey will be de-identified and aggregated before being publicly shared to ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2
... ... and their families asked to share stories around men,s health issues , ... Minneapolis, Minnesota (PRWEB) June 15, 2009 -- In ... Scoop is calling on men and their family members to share their health-related experiences ...
... , CHICAGO, June 15 The following statement is attributable ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) ... honored that President Obama will speak directly to physicians at ... to health reform this year that provides all Americans with ...
... announced today the first commercial, plant-based diamine oxidase (DAO). Dr. ... that this new diamine oxidase is orders of magnitude more ... is available as a lyophilized powder. Price will be $200 ... test assays to detect spoilage by the presence of histamines ...
... To Be Released Tuesday Show Employer Health Mandate Would Help ... , WASHINGTON, June 15 Hundreds of economists will ... nation,s health care system, and health care experts will release ... a conference call with reporters on Tuesday. , , ...
... delivery of gene therapy suppresses tumors in mice , ... able to fight lung cancer using gene therapy delivered by ... lung cancer that were treated with a vaporized viral vector ... than untreated mice. , Researchers also found that treated mice ...
... JOLLA, Calif., June 15 Transdel Pharmaceuticals, Inc. (OTC ... developing non-invasive, topically administered products, announced that they anticipate ... of Ketotransdel(R) during the third quarter of 2009. ... of a randomized, double-blind, placebo controlled trial to evaluate ...
Cached Medicine News:Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 2Health News:Tough Guys Speak Out About Men's Health On The Healthcare Scoop 3Health News:AMA Committed to Health Reform, Welcomes President Obama 2Health News:Coming Soon: Lung-Cancer Spray? 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3
Microcontroller-based isolated electrosurgical generator, designed for all general purpose surgical procedures. Unit includes: Instant Response technology, adaptive REM system, isolated output, CEM c...
Maddox rod and occluder...
Long handle occluder - White...
Double Ended Occluders...
Medicine Products: